CN1137096C - 制备(-)顺式-3-羟基-1-甲基-4-(2,4,6-三甲氧基苯基)-哌啶的方法 - Google Patents
制备(-)顺式-3-羟基-1-甲基-4-(2,4,6-三甲氧基苯基)-哌啶的方法 Download PDFInfo
- Publication number
- CN1137096C CN1137096C CNB988132311A CN98813231A CN1137096C CN 1137096 C CN1137096 C CN 1137096C CN B988132311 A CNB988132311 A CN B988132311A CN 98813231 A CN98813231 A CN 98813231A CN 1137096 C CN1137096 C CN 1137096C
- Authority
- CN
- China
- Prior art keywords
- methyl
- trimethoxyphenyl
- tetrahydropyridine
- vii
- hydrobromide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19802449A DE19802449A1 (de) | 1998-01-23 | 1998-01-23 | Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin |
| DE19802449.5 | 1998-01-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1284065A CN1284065A (zh) | 2001-02-14 |
| CN1137096C true CN1137096C (zh) | 2004-02-04 |
Family
ID=7855418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988132311A Expired - Lifetime CN1137096C (zh) | 1998-01-23 | 1998-12-18 | 制备(-)顺式-3-羟基-1-甲基-4-(2,4,6-三甲氧基苯基)-哌啶的方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6225473B1 (enExample) |
| EP (1) | EP1049674B1 (enExample) |
| JP (1) | JP4585116B2 (enExample) |
| KR (1) | KR100567941B1 (enExample) |
| CN (1) | CN1137096C (enExample) |
| AR (1) | AR015218A1 (enExample) |
| AT (1) | ATE355270T1 (enExample) |
| AU (1) | AU762407B2 (enExample) |
| BR (1) | BR9814774B1 (enExample) |
| CA (1) | CA2318946C (enExample) |
| CY (1) | CY1106511T1 (enExample) |
| CZ (1) | CZ298852B6 (enExample) |
| DE (2) | DE19802449A1 (enExample) |
| DK (1) | DK1049674T3 (enExample) |
| ES (1) | ES2281943T3 (enExample) |
| HU (1) | HU227928B1 (enExample) |
| IL (1) | IL137422A (enExample) |
| NO (1) | NO321933B1 (enExample) |
| NZ (1) | NZ505897A (enExample) |
| PL (1) | PL190790B1 (enExample) |
| PT (1) | PT1049674E (enExample) |
| RU (1) | RU2265595C2 (enExample) |
| SK (1) | SK285883B6 (enExample) |
| TR (1) | TR200002146T2 (enExample) |
| WO (1) | WO1999037615A1 (enExample) |
| ZA (1) | ZA99477B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437136B2 (en) * | 1998-01-23 | 2002-08-20 | Aventis Pharma Deutschland Gmbh | Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine |
| DE19809649A1 (de) * | 1998-03-06 | 1999-09-09 | Hoechst Marion Roussel De Gmbh | Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester |
| JP6851978B2 (ja) | 2015-04-20 | 2021-03-31 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ミトコンドリアプロファイリングによるアルボシジブ応答の予測 |
| WO2016187316A1 (en) | 2015-05-18 | 2016-11-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
| BR112018002427A8 (pt) | 2015-08-03 | 2022-10-18 | Tolero Pharmaceuticals Inc | Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| EP3362471B1 (en) | 2016-12-19 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
| US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| CN110577974B (zh) * | 2019-09-10 | 2021-07-20 | 杭州澳赛诺生物科技有限公司 | 手性3-羟基-1,2,3,6-四氢吡啶的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (enExample) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
| DE3836676A1 (de) * | 1988-10-28 | 1990-05-03 | Hoechst Ag | Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| US5849733A (en) * | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| US5908934A (en) * | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
-
1998
- 1998-01-23 DE DE19802449A patent/DE19802449A1/de not_active Withdrawn
- 1998-12-18 RU RU2000122151/04A patent/RU2265595C2/ru active
- 1998-12-18 PL PL342064A patent/PL190790B1/pl unknown
- 1998-12-18 EP EP98966836A patent/EP1049674B1/de not_active Expired - Lifetime
- 1998-12-18 DK DK98966836T patent/DK1049674T3/da active
- 1998-12-18 AU AU25135/99A patent/AU762407B2/en not_active Expired
- 1998-12-18 CA CA002318946A patent/CA2318946C/en not_active Expired - Lifetime
- 1998-12-18 ES ES98966836T patent/ES2281943T3/es not_active Expired - Lifetime
- 1998-12-18 AT AT98966836T patent/ATE355270T1/de active
- 1998-12-18 CN CNB988132311A patent/CN1137096C/zh not_active Expired - Lifetime
- 1998-12-18 BR BRPI9814774-9A patent/BR9814774B1/pt not_active IP Right Cessation
- 1998-12-18 TR TR2000/02146T patent/TR200002146T2/xx unknown
- 1998-12-18 NZ NZ505897A patent/NZ505897A/xx not_active IP Right Cessation
- 1998-12-18 WO PCT/EP1998/008327 patent/WO1999037615A1/de not_active Ceased
- 1998-12-18 PT PT98966836T patent/PT1049674E/pt unknown
- 1998-12-18 US US09/600,775 patent/US6225473B1/en not_active Expired - Lifetime
- 1998-12-18 DE DE59813924T patent/DE59813924D1/de not_active Expired - Lifetime
- 1998-12-18 SK SK1097-2000A patent/SK285883B6/sk not_active IP Right Cessation
- 1998-12-18 KR KR1020007007959A patent/KR100567941B1/ko not_active Expired - Lifetime
- 1998-12-18 IL IL13742298A patent/IL137422A/xx not_active IP Right Cessation
- 1998-12-18 JP JP2000528539A patent/JP4585116B2/ja not_active Expired - Lifetime
- 1998-12-18 CZ CZ20002665A patent/CZ298852B6/cs not_active IP Right Cessation
- 1998-12-18 HU HU0100649A patent/HU227928B1/hu unknown
-
1999
- 1999-01-21 AR ARP990100242A patent/AR015218A1/es active IP Right Grant
- 1999-01-22 ZA ZA9900477A patent/ZA99477B/xx unknown
-
2000
- 2000-07-04 NO NO20003454A patent/NO321933B1/no not_active IP Right Cessation
-
2007
- 2007-04-12 CY CY20071100513T patent/CY1106511T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0906278B1 (en) | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones | |
| EP3856744A1 (en) | Manufacture of compounds and compositions for inhibiting the activity of shp2 | |
| CN1137096C (zh) | 制备(-)顺式-3-羟基-1-甲基-4-(2,4,6-三甲氧基苯基)-哌啶的方法 | |
| CN1108239A (zh) | 杀虫(菌)剂及其中间体的制备方法 | |
| US6437136B2 (en) | Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine | |
| CN110372708B (zh) | 一种5H-苯并[c]咪唑并[1,2-a]氮杂环庚烯-6-羧酸类化合物的合成方法 | |
| HK1033319B (en) | Method for producing (-)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxy-phenyl)-piperidine | |
| CN1248263A (zh) | 甲酰氨基－4－氮杂甾族化合物的制备方法 | |
| CN1989097A (zh) | 用于制备非对映异构体富集的化合物的方法 | |
| CN116262727A (zh) | 四取代苯乙烯类轴手性化合物及其合成方法 | |
| JP3088328B2 (ja) | 光学活性２−フェニル−２−（２’−ピペリジニル） 酢酸エステル誘導体の製造方法 | |
| CN1102143C (zh) | 生产(9α,13α,14α)－1－(3－甲氧基吗啡喃－17－基)烷酮的方法 | |
| CN1561337A (zh) | 2－基苯并二氢吡喃衍生物的立体有择合成方法 | |
| EP0006355A1 (en) | Mixed anhydride steroid intermediate and process for preparing steroid intermediates | |
| KR100696187B1 (ko) | 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법 | |
| CN1323296A (zh) | 合成4－取代n－[(链－2－烯－1－基)氧基]－和n－芳烷氧基－2,2,6,6－四烷基哌啶的方法 | |
| JPH10279552A (ja) | ７−（ｎ−置換アミノ）−２−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法 | |
| CN87104694A (zh) | 制备6-氨基-1，2-二氢-1-羟基-2-亚氨基-4-哌啶子基嘧啶的方法 | |
| MXPA00006631A (en) | Method for producing (-)cis-3-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl)-piperidine | |
| JP2000515534A (ja) | ３，３―二置換ピペリジンの製造方法 | |
| WO2004026855A1 (en) | Method for manufacture of dihydroisobenzofuran derivatives | |
| JPH08301825A (ja) | ３’−置換−（２−カルボキシシクロプロピル）グリシン | |
| CN112939848A (zh) | 一种布比卡因及其中间体(s)-2-哌啶甲酸的制备方法 | |
| JPH0762024B2 (ja) | Ｄ−グルコフラノース又はｄ−キシロフラノース誘導体の製法 | |
| KR20060125218A (ko) | 광학활성 벤족사진 유도체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SANOFI- AVENTIS GERMAN CO., LTD. Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Frankfurt, Germany Patentee after: AVENTIS PHARMA DEUTSCHLAND GmbH Address before: Frankfurt, Germany Patentee before: AVENTIS PHARMA DEUTSCHLAND GmbH |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040204 |